Pfizer Inc (NYSE:PFE)
| 40.51 Delayed Data As of Jan 17 |  -0.10 / -0.25%Today’s Change | 33.97 Today|||52-Week Range 44.56 | +3.39% Year-to-Date |
Latest PFE News | Press Releases
| 2 Biotechs Battling Immune Diseases Jan 19 / MotleyFool.com - Paid Partner Content | Is Pfizer's Stock a Buy? Jan 14 / MotleyFool.com - Paid Partner Content |
| Why Pfizer Stock Fell 10.2% in 2019 Jan 16 / MotleyFool.com - Paid Partner Content | Biogen Buys Azheimer's and Parkinson's Drug From Pfizer Jan 13 / MotleyFool.com - Paid Partner Content |
| 5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals Jan 16 / MotleyFool.com - Paid Partner Content | Here's Why SpringWorks Therapeutics Climbed 69% in December Jan 12 / MotleyFool.com - Paid Partner Content |
| New Research Shows Probiotics Can Help Prevent Parkinson's Jan 14 / MotleyFool.com - Paid Partner Content | Here's Why Mylan Fell 26.6% in 2019 Jan 10 / MotleyFool.com - Paid Partner Content |
| Will Theravance Biopharma Finally Break Out in 2020? Jan 14 / MotleyFool.com - Paid Partner Content | Why Pfizer Is My Drug Stock of Choice Jan 10 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 40.61 |
| Today’s open | 40.57 |
| Day’s range | 40.42 - 40.81 |
| Volume | 21,901,267 |
| Average volume (3 months) | 18,766,466 |
| Market cap | $224.2B |
Data as of 6:30pm ET, 01/17/2020
Growth & Valuation
| Earnings growth (last year) | -46.78% |
| Earnings growth (this year) | -1.03% |
| Earnings growth (next 5 years) | +6.70% |
| Revenue growth (last year) | +2.10% |
| P/E ratio | 14.2 |
| Price/Sales | 4.86 |
| Price/Book | 3.65 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +0.83 | +0.87% |
| MRKMerck | -0.21 | -0.23% |
| BMYBristol-Myers Squibb | -0.06 | -0.09% |
| AZNAstraZeneca | +0.82 | +1.62% |
Data as of 6:30pm ET, 01/17/2020
Financials
| Next reporting date | January 28, 2020 |
| EPS forecast (this quarter) | $0.57 |
| Annual revenue (last year) | $53.6B |
| Annual profit (last year) | $11.2B |
| Net profit margin | 20.77% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
